What are the chances of contracting measles after receiving the Measles, Mumps, and Rubella (MMR) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Chances of Contracting Measles After MMR Vaccination

The MMR vaccine is highly effective at preventing measles, with a 95% protection rate after one dose and 96% after two doses, meaning the chance of getting measles after proper vaccination is approximately 4-5% after one dose and 3-4% after two doses. 1

Vaccine Effectiveness Against Measles

The protection provided by MMR vaccination is substantial and well-documented:

  • After one dose: 95% effective at preventing measles (RR 0.05,95% CI 0.02 to 0.13), leaving approximately a 5% chance of infection if exposed 1
  • After two doses: 96% effective at preventing measles (RR 0.04,95% CI 0.01 to 0.28), leaving approximately a 4% chance of infection if exposed 1
  • Post-exposure prophylaxis: Even when given after measles exposure, at least one dose provides 74% protection (RR 0.26,95% CI 0.14 to 0.50) 1

Long-Term Antibody Protection

While antibody levels decline over time, protection against disease remains largely intact:

  • At 10 years post-vaccination: 93.7% of two-dose recipients maintained protective antibody levels against measles 2
  • Antibody waning: Measles neutralizing antibodies decline annually, but the pattern and magnitude vary by individual baseline response 2
  • Clinical significance: Even when antibodies wane, protection against actual measles disease is largely retained, unlike mumps where waning is more clinically significant 2

Vaccine-Related Measles-Like Symptoms vs. True Infection

A critical distinction must be made between vaccine-related symptoms and actual measles infection:

  • Vaccine-induced rash: Approximately 5% of vaccinated persons develop a transient measles-like rash 7-10 days after vaccination 3
  • Timing: These symptoms typically occur 5-14 days post-vaccination due to limited replication of the attenuated vaccine virus 4
  • Not contagious: These vaccine-related symptoms represent a reaction to the attenuated virus, not true measles infection 4
  • Diagnostic confusion: Positive measles tests within 14 days of vaccination likely represent vaccine virus detection rather than wild-type measles, given the extremely low incidence of wild-type measles 4

Household and Community Transmission Prevention

The vaccine also provides substantial protection against transmission:

  • After one dose: 81% effective at preventing transmission to household contacts (RR 0.19,95% CI 0.04 to 0.89) 1
  • After two doses: 85% effective at preventing transmission (RR 0.15,95% CI 0.03 to 0.75) 1
  • After three doses: 96% effective at preventing transmission (RR 0.04,95% CI 0.01 to 0.23) 1

Immunity Gaps and Special Populations

Certain populations may have lower protection rates:

  • Women of childbearing age: Studies show only 75% baseline measles seropositivity in some adult populations, increasing to 98% after MMR vaccination 5
  • Inadequate childhood vaccination: Adults who received inadequate childhood vaccination or were vaccinated before 12 months of age may have suboptimal protection 3
  • Inactivated vaccine recipients (1963-1967): Those who received killed measles vaccine require revaccination with two doses of live MMR vaccine 3

Clinical Bottom Line

The overwhelming majority (95-96%) of properly vaccinated individuals will not contract measles even when exposed. The small percentage who do contract measles after vaccination typically experience milder disease than unvaccinated individuals. The benefits of vaccination far outweigh the minimal risk of vaccine failure, particularly given that natural measles infection carries substantially higher risks of serious complications including encephalopathy (1 per 1,000 cases) compared to the vaccine (approximately 1 per 2 million doses) 3.

Related Questions

What is the efficacy of the first dose of the measles, mumps, and rubella (MMR) vaccine?
Does it make sense to administer an additional dose of the Measles, Mumps, and Rubella (MMR) vaccine to someone who was previously vaccinated in 1979 or 1990 if they are traveling to an area with a high prevalence of measles?
Can a 6-month-old infant receive the Measles, Mumps, and Rubella (MMR) vaccine?
Is a measles vaccine needed if a patient has completed the MMR (Measles, Mumps, and Rubella) series but has no record of a standalone measles vaccine?
Is there a separate measles vaccine available apart from the Measles, Mumps, and Rubella (MMR) vaccine?
What is the preferred prophylaxis, Low Molecular Weight Heparin (LMWH) or Intravenous (IV) heparin, for postpartum patients with no comorbidities and preserved renal function to prevent Venous Thromboembolism (VTE)?
What is the alternative treatment for moderate to severe alcohol withdrawal symptoms if lorazepam (Ativan) is not available, using diazepam (Valium)?
What research proposal is applicable to Filipino patients regarding antimicrobial stewardship programs?
What is the preferred treatment for alcoholic withdrawal in a patient with Acute Respiratory Distress Syndrome (ARDS) and elevated liver enzymes, specifically Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT), when lorazepam is not available and only diazepam is available?
What is the recommended dose of Neomycin (Neomycin) for the treatment of Small Intestine Bacterial Overgrowth (SIBO)?
What is the management plan for repeated unexplained third trimester intrauterine death (IUD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.